BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is one of the 10 Stocks Dominating Today’s Market Action.

BioCryst grew its share prices by 7.10 percent on Thursday to close at $9.81 apiece as investors repositioned portfolios following rumors that it is set to be acquired by a large-cap US biopharmaceutical company.

The report first broke out on Monday from a website about deals and dealmakers, saying that a US-based pharmaceutical giant is setting its sights on BioCryst Pharmaceuticals Inc (NASDAQ:BCRX).

As of writing, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has yet to confirm or deny the said report.

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz

Last month, it announced strong earnings performance in 2025, having swung to a net income of $263.86 million last year from an $88.88 million net loss in 2024. Total revenues soared by 94 percent to $874.8 million from $450.7 million year-on-year, helped by the successful $243.3 million sale of its European Orladeyo business to Neopharmed Gentili. Orladeyo is a prescription oral medicine for preventing hereditary angioedema attacks in adults and children 12 years and older.

In the fourth quarter alone, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) incurred a $245.8 million net income, reversing a $26.79 million net loss in the same period a year earlier. Total revenues more than tripled to $406.5 million from $131.5 million year-on-year.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.